Knowledge of the previous testing behaviour of newly diagnosed individuals may better inform recommendations for testing frequency in these key groups, such as assessing the time between last-known negative and first positive HIV tests, or inter-test interval (ITI). 18 We examined ITI among persons newly diagnosed with HIV in BC, focusing on MSM and IDU, as key populations affected by HIV in our province and populations for whom test frequency recommendations are often tailored. To do this, we used provincial HIV surveillance and laboratory testing data to describe previous history of testing and ITI among new HIV diagnoses and to identify factors associated with longer ITI among MSM and IDU.
METHODS
We calculated ITI as the time between the dates of the last recorded negative test (in the ten years prior to diagnosis) and first reactive test leading to a confirmed HIV diagnosis. Surveillance records for individuals with a confirmed new diagnosis of HIV in BC (based on provincial case definitions 19 ) between January 2006 and December 2011 were linked to laboratory HIV testing data from the Public Health Microbiology & Reference Laboratory (>90% of HIV tests in BC) through deterministic (unique personal health number) and probabilistic matching (name and birthdate). The date of last negative test was taken from either laboratory or surveillance data (the latter if ≥30 days after last laboratory test, to capture later self-reported negative tests such as rapid or out-of-province testing). Based on clinical opinion, we excluded individuals with ITI ≤30 days as we considered the negative test to possibly be related to the same testing episode (e.g., repeat testing after a risk event).
To understand the potential impact of targeted testing strategies on existing testing patterns, we calculated the proportion of individuals having an ITI ≤3, ≤6, and ≤12 months, and used linear regression to identify variables associated with longer ITI for MSM and IDU separately (who constituted 71% of all cases during this period). We considered the following potentially associated with ITI: diagnosis year, gender, age, ethnicity (Caucasian, Aboriginal, other), region (Vancouver residence, other), known HIV positive partner, test reporting option (whether individual chose to be reported to public health non-nominally without identifiers, or nominally) and stage of infection at diagnosis (acute, advanced, other). Acute HIV infection was defined as detection of HIV DNA or RNA by nucleic acid amplification testing, or detection of p24 antigen with confirmation by neutralization assay in the absence of a confirmed antibody response. Advanced stage of infection was defined as having an AIDS diagnosis within 12 months of being diagnosed with HIV. The proportion of individuals with a previous negative test was compared across covariates using a two-sided Chi-square test (p<0.05 considered statistically significant). ITI was logtransformed to ensure normality, and univariate and multivariable linear regression modeling was conducted to evaluate correlates of ITI. Stage of infection was considered a potential outcome of ITI and excluded from multivariable analysis. Variables were individually removed from a full model to examine the effects of confounding, and a final model was selected based on Akaike Information Criterion. Analysis was conducted using R version 2.11.1 (2010-05-31).
Ethics approval was not required as this study was consistent with the public health mandates of the BC Centre for Disease Control and the Provincial Public Health Microbiology & Reference Laboratory.
RESULTS
During the study period, there were 2,023 new HIV diagnoses in BC, of which 19 (0.9%) were excluded for ITI ≤30 days. Of the remainder, 1,116/2,004 (55.7%) had a recorded negative test, including 59.6% (580/973) of MSM and 72.7% (323/444) of IDU. All variables, with the exception of gender and year of diagnosis, were significantly associated with having a previous negative HIV test (Table 1) .
The distribution of ITI was highly skewed for all groups, with an overall median ITI of 20 months [inter-quartile range (IQR) (Figure 1 , Table 1 ). Overall in BC, we observed significant differences (p<0.05) in median ITI by year of diagnosis (with the lowest median ITI in 2011), and significantly lower ITI among Vancouver residents, individuals with a known HIV-positive partner, and individuals testing non-nominally. We also found a significant trend for median ITI by age, with higher ITI at older ages.
ITI differed significantly by exposure group (p<0.05); median ITI was lowest for MSM at 15 months [IQR 7-37], with 8%, 20%, and 41% having a last negative test within 3, 6, and 12 months prior to diagnosis, respectively. For IDU, the corresponding values were median 21 months [IQR 9-46] and 3%, 14%, and 33%, respectively. Among MSM (Table 2a) , on univariate analysis longer ITI was significantly associated with older age, residence outside of Vancouver, not having a known HIV-positive partner, and non-acute stage of HIV infection at diagnosis. Older age, residence outside Vancouver, and not having a known HIVpositive partner were significant on full multivariable analysis (following exclusion of stage of infection), and were selected into the final MSM model. For IDU, longer ITI was associated with earlier year of diagnosis, older age, and advanced HIV disease at diagnosis. On full multivariable analysis (excluding stage of infection), only older age remained significant (Table 2b) ; age and region of residence were selected into the final IDU model.
DISCUSSION
We evaluated ITI for newly diagnosed individuals in BC between 2006 and 2011 and found an overall median ITI of 20 months [IQR 8-46 months], and that ITI was highly skewed across all categories. ITI differed by exposure category and was lowest among MSM and IDU at median 15 [IQR 7-37] and 21 months [IQR 9-46], respectively. Fewer than half of newly diagnosed MSM and IDU had an ITI <1 year, and more frequent testing as per typical recommendations (i.e., at 3-and 6-month intervals) in these high-risk MSM and IDU appeared low. In multivariable analysis, we found longer ITI among both MSM and IDU was associated with older age, and among MSM with residence outside Vancouver and not being known to have an HIV-positive partner.
Using ITI as a metric for monitoring HIV testing patterns appears only recently in the published literature, 18 and there are few published reports to which we can appropriately compare our findings among persons newly diagnosed with HIV. We identified three similar studies which have used HIV surveillance Distribution 20 A recent report using HIV surveillance data from Seattle/King County in Washington, USA found among MSM diagnosed with HIV between 2004-2010 a median ITI of 12 months, with 13% and 49% having an ITI ≤3 and ≤12 months, respectively; no temporal trend was detected. 21 A second report, also using HIV surveillance data from Seattle/King County for all individuals diagnosed with HIV between 2005-2009, found a median ITI of 13 months overall. 18 These differences in median ITI from those in our study may be related to geographic differences in the populations studied, such as population density, access to testing, or testing campaigns. Similar factors may explain why we have demonstrated in our study differences in ITI for individuals residing in Vancouver compared to those residing in other parts of BC.
This analysis suggests that individuals with the highest risk for HIV infection (as demonstrated by their new HIV diagnosis) may benefit from more frequent testing as this may reduce ITI and lead to earlier HIV diagnosis. Initiatives to increase HIV testing frequency among MSM and IDU populations in BC may have an impact in this regard, particularly for older individuals and nonVancouver residents. In consideration of this analysis, the STOP HIV/AIDS Initiative endorsed recommendations for annual HIV testing among MSM and IDU, with more frequent testing (every 3 months) for individuals at higher risk. While developing recommendations for clinicians and programs is important, achieving increased frequency of HIV testing requires a comprehensive approach. Expanding routine offer of HIV testing in health care settings may contribute by providing more frequent testing opportunities for all exposure groups, including MSM and IDU. 22 Expansion of targeted testing strategies and programs may be particularly important for MSM in BC, who in 2011 comprised 57% and 46% of incident and prevalent infections, respectively, and where new HIV diagnoses per year remain elevated (in contrast to recent declining trends among IDU). 19, 23, 24 Expansion of established interventions such as lowthreshold models of testing, HIV testing as part of STI care, and rapid HIV testing, as well as new interventions such as texting testing reminders or internet-based testing, should be considered. [25] [26] [27] We recognize that there are limitations of this analysis due to the use of administrative data (surveillance and laboratory data). The proportion of individuals not having a documented previous negative test may be due to inability to link surveillance and laboratory data as tests or case reports may contain partial identifiers, due to non-nominal testing or reporting. Rapid testing has been increasingly available since 2010 and is not captured in provincial laboratory data (although representing <5% of total tests). For these reasons, we may have misclassified individuals based on prior test history, excluding previouslytested individuals from the analysis, or over-estimated ITI for some individuals. However, a strength of our study is our ability to include laboratory data and self-reported prior negative tests, as this is consistently documented in surveillance data during public health follow-up. This may explain why we found a more consistent association between ITI and stage of disease at diagnosis than a recently published study which relied on surveillance data only; although we also recognize discrepancies within our data in this regard (e.g., as some individuals with advanced HIV disease at diagnosis were identified as having a recent negative HIV test). 18 We are also unable to describe ITI among individuals with a negative HIV test in BC overall and by exposure category, and as such we are unable to compare ITI between HIV-negative and newly diagnosed individuals in total or among MSM and IDU. However, describing ITI among newly diagnosed MSM and IDU is most relevant as these represent individuals at highest risk of infection (by virtue of a new HIV diagnosis).
We conclude that there is room for improvement in the frequency of HIV testing (as reflected by ITI) among key populations such as MSM and IDU in BC. Continued implementation and expansion of strategies to increase both overall HIV testing and test frequency among MSM and IDU are being pursued in BC, with expansion of the STOP HIV/AIDS program provincially in 2013. We note encouragingly that the overall ITI for the province decreased in 2011, and that more recent year of diagnosis was significantly associated with lower ITI among IDU. However, no reduction in ITI was observed among MSM, who comprise the majority of new HIV diagnoses in BC. As seek, test and treat approaches expand in BC as well as elsewhere, our findings suggest that ITI may be a useful indicator for monitoring the success of entry into the diagnosis, engagement and treatment cascade of HIV care. 
